Please use this identifier to cite or link to this item: https://doi.org/10.1186/s40779-021-00342-3
DC FieldValue
dc.titleUnderstanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
dc.contributor.authorPang, Natalie Yan-Lin
dc.contributor.authorPang, Alexander Shao-Rong
dc.contributor.authorChow, Vincent T
dc.contributor.authorWang, De-Yun
dc.date.accessioned2022-06-08T09:54:37Z
dc.date.available2022-06-08T09:54:37Z
dc.date.issued2021-08-31
dc.identifier.citationPang, Natalie Yan-Lin, Pang, Alexander Shao-Rong, Chow, Vincent T, Wang, De-Yun (2021-08-31). Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. MILITARY MEDICAL RESEARCH 8 (1). ScholarBank@NUS Repository. https://doi.org/10.1186/s40779-021-00342-3
dc.identifier.issn20957467
dc.identifier.issn20549369
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/226769
dc.description.abstractSARS-CoV-2 is a newly identified member of the coronavirus family that has caused the Coronavirus disease 2019 (COVID-19) pandemic. This rapidly evolving and unrelenting SARS-CoV-2 has disrupted the lives and livelihoods of millions worldwide. As of 23 August 2021, a total of 211,373,303 COVID-19 cases have been confirmed globally with a death toll of 4,424,341. A strong understanding of the infection pathway of SARS-CoV-2, and how our immune system responds to the virus is highly pertinent for guiding the development and improvement of effective treatments. In this review, we discuss the current understanding of neutralising antibodies (NAbs) and their implications in clinical practice. The aspects include the pathophysiology of the immune response, particularly humoral adaptive immunity and the roles of NAbs from B cells in infection clearance. We summarise the onset and persistence of IgA, IgM and IgG antibodies, and we explore their roles in neutralising SARS-CoV-2, their persistence in convalescent individuals, and in reinfection. Furthermore, we also review the applications of neutralising antibodies in the clinical setting—from predictors of disease severity to serological testing to vaccinations, and finally in therapeutics such as convalescent plasma infusion.
dc.language.isoen
dc.publisherBMC
dc.sourceElements
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectMedicine, General & Internal
dc.subjectGeneral & Internal Medicine
dc.subjectSARS-CoV-2
dc.subjectCoronavirus disease 2019
dc.subjectNeutralising antibodies
dc.subjectPersistence
dc.subjectSpike glycoprotein
dc.subjectReceptor-binding domain
dc.subjectB cells
dc.subjectT cells
dc.subjectConvalescent plasma
dc.subjectSERUM ANTIBODY
dc.subjectCOVID-19
dc.subjectIGG
dc.subjectINFECTION
dc.subjectRESPONSES
dc.subjectSPIKE
dc.typeReview
dc.date.updated2022-06-07T05:26:39Z
dc.contributor.departmentDEPT OF MICROBIOLOGY & IMMUNOLOGY
dc.contributor.departmentDEPT OF OTOLARYNGOLOGY
dc.description.doi10.1186/s40779-021-00342-3
dc.description.sourcetitleMILITARY MEDICAL RESEARCH
dc.description.volume8
dc.description.issue1
dc.published.statePublished
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice.pdf1.98 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.